Icatibant – Prof. Marcus Maurer

The icatibant outcome survey: 10 years of experience with icatibant for patients with hereditary angioedema

177.

Maurer, M.⁺, Aberer, W., Caballero, T., Bouillet, L., Grumach, A. S., Botha, J., Andresen, I., and Longhurst, H. J. for the IOS study group: the icatibant outcome survey: 10 years of experience with icatibant for patients with hereditary angioedema. Clin. Exp. Allergy 2022: 52; 1048-1058. IF: 6.10

r.177

The icatibant outcome survey: treatment of laryngeal angioedema attacks

234	Longhurst, H. J.+, Aberer, W., Bouillet, L., Caballero, T., Maurer, M. Fabien, V., Zanichelli, A.: The icatibant outcome survey: treatment of laryngeal angioedema attacks. Eur. J. Emerg. Med. 2016: 23; 224-227. IF: 2.02

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey

263	Longhurst, H. J.+, Zanichelli, A., Caballero, T., Bouillet, L., Aberer, W., Maurer, M. Fain, O., Fabien, V., and Andresen, I.: Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the icatibant outcome survey. Clin. Exp. Immunol. 2017: 188; 148-153. IF: 3.54

Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice

273	Zanichelli, A., Maurer, M. Aberer, W., Caballero, T., Longhurst, H., Bouillet, L., Fabien, V., and Andresen, I.: Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice. Allergy 2017: 72; 994-998. IF: 6.05

o.273

Analysis of characteristics associated with reinjection of icatibant: Results from the Icatibant Outcome Survey

214	Longhurst, H.+, Aberer, W., Bouillet, L., Caballero, T., Fabien, V., Zanichelli, A., and Maurer, M.: Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. Allergy Asthma Proc. 2015: 36; 399-406. IF: 2.70

Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals

212

Hernández Fernández de Rojas, D.+, Ibáňez, E., Longhurst, H., Maurer, M. Fabien, V., Aberer, W., Bouillet, L., Zanichelli, A., and Caballero, T.: Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. Int. Arch. Allergy Immunol. 2015: 167; 21-28. IF: 2.67

New topics in bradykinin research

56.	Maurer, M., Bader, M., Bas, M., Bossi, F., Cicardi, M., Cugno, M., Howarth, P., Kaplan, A., Kojda, G., Leeb-Lundberg, F., Lötvall, J., and Magerl, M.: New topics in bradykinin research. Allergy 2011: 66; 1397-1406. IF: 6.27

Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives

51.	Maurer, M. and Magerl, M.: Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives. J. Dtsch. Dermatol. Ges. 2011: 9; 99-107. IF: 1.47

Hereditary angioedema: an update on available therapeutic options

45.	Maurer, M. and Magerl, M.: Hereditary angioedema: an update on available therapeutic options. J. Dtsch. Dermatol. Ges. 2010: 8; 663-672. IF: 1.48

Treatment of acute attacks of hereditary angioedema (HAE) with the bradykinin B2 receptor antagonist icatibant

37.	Magerl, M., Keßler, B., and Maurer, M.: Treatment of acute attacks of hereditary angioedema (HAE) with the bradykinin B2 receptor antagonist icatibant. Rev. Port. Imunoalergologia 2010: 18; 207-214. IF: N/A